Back

Effects of tafamidis on quantification of myocardial amyloid deposits in patients with transthyretin amyloid cardiomyopathy

30 June 2021 (14:00 - 15:00)
Organised by:
Congress Presentation Part of: Myocardial Disease Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2021

About the speaker

Photo
Doctor Rene Rettl

Medical University of Vienna, Vienna (Austria)

7 More presentations in this session

Presentation thumbnail
Predictive role of myocardial fibrosis and extracellular myocardial volume in sudden cardiac death and ventricular tachyarrhythmias in patients with hypertrophic cardiomyopathy
Mrs N. Rineiska (Minsk, BY)
Abstract Slides Video
Presentation thumbnail
Alcohol septal ablation is safe in young patients
Doctor A. Batzner (Wurzburg, DE)
Abstract Slides Video
Presentation thumbnail
Mavacamten improves symptoms of shortness of breath in patients with obstructive hypertrophic cardiomyopathy (HCM): analysis of the HCM Symptom Questionnaire in the phase 3 EXPLORER trial
Doctor S. Naidu (New York, US)
Abstract Slides Video
Presentation thumbnail
Left atrial strain in cardiac amyloidosis
Doctor I. Fabiani (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
DPD scintigraphy fails to detect transthyretin cardiac amyloidosis in Val30Met mutation carriers with early onset disease.
Doctor A. Olivella (Barcelona, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Myocardial Disease

The Event

Event poster

Heart Failure 2021

30 June 2021 14:00 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources